Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

A leading pharmaceutical trade group urged the Department of Commerce not to place tariffs on the sector as the window for ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

Federal appeals court overturns order blocking Avadel Pharmaceuticals from seeking FDA approval for Lumryz in idiopathic ...

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...

NewAmsterdam's obicetrapib reduced Lp(a) by 45% in Phase 3; C4 Therapeutics advances cemsidomide while dropping CFT1946; Vivo ...

Theriva Biologics' VCN-01 plus chemotherapy showed improved survival in pancreatic cancer patients vs. chemo alone in Phase ...

Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...

CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...